297 related articles for article (PubMed ID: 32126312)
1. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
2. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
3. The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study.
Oh DJ; Nam JH; Lee HS; Moon YR; Lim YJ
Korean J Intern Med; 2024 Mar; 39(2):228-237. PubMed ID: 38321358
[TBL] [Abstract][Full Text] [Related]
4. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
5. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
6. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
7. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
Abrahamsen B; Vestergaard P
Bone; 2013 Nov; 57(1):269-71. PubMed ID: 23973557
[TBL] [Abstract][Full Text] [Related]
9. Association between proton pump inhibitor use and risk of fracture: A population-based case-control study.
Kim JJ; Jang EJ; Park J; Sohn HS
PLoS One; 2020; 15(7):e0235163. PubMed ID: 32730257
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study.
Miyano S; Michihata N; Sada KE; Uda K; Matsui H; Fushimi K; Nangaku M; Yasunaga H
Rheumatology (Oxford); 2021 Apr; 60(4):1717-1723. PubMed ID: 33067623
[TBL] [Abstract][Full Text] [Related]
12. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
14. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
Lyu B; Hansen KE; Jorgenson MR; Astor BC
Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
[TBL] [Abstract][Full Text] [Related]
15. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
Lewis JR; Barre D; Zhu K; Ivey KL; Lim EM; Hughes J; Prince RL
J Bone Miner Res; 2014 Nov; 29(11):2489-97. PubMed ID: 24825180
[TBL] [Abstract][Full Text] [Related]
16. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
18. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
19. A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients.
Fleishman NR; Richardson T; Attard TM
Curr Med Res Opin; 2022 Apr; 38(4):565-570. PubMed ID: 35112645
[TBL] [Abstract][Full Text] [Related]
20. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]